Atenolol/Chlorthalidone — Discount Pricing

Atenolol/Chlorthalidone is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.

Atenolol/Chlorthalidone Pricing

Pricing type	Price
TheDrugClub	Discount pricing may be available
Typical Retail	$128.00

Discount pricing may be available; confirm the price with the dispensing pharmacy.

About Atenolol/Chlorthalidone

Atenolol/Chlorthalidone is a prescription medication. Ask your doctor if Atenolol/Chlorthalidone is right for you.

How to Check Atenolol/Chlorthalidone Pricing

Join TheDrugClub for $19.95/month
Receive your member card by email
Present your card at a participating pharmacy
Check active-formulary eligibility or available discount pricing

Atenolol/Chlorthalidone at Participating Pharmacies

Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.

What Atenolol/Chlorthalidone is approved for (FDA label)

Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals.

Source: Read the full FDA label on DailyMed. Label effective date: August 27, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Atenolol/Chlorthalidone (FDA label)

Atenolol and chlorthalidone tablets are usually well tolerated in properly selected patients. Most adverse effects have been mild and transient. The adverse effects observed for atenolol and chlorthalidone tablets are essentially the same as those seen with the individual components. Atenolol The frequency estimates in the following table were derived from controlled studies in which adverse reactions were either volunteered by the patient (US studies) or elicited, e.g., by checklist (foreign studies). The reported frequency of elicited adverse effects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered. Where frequency of adverse effects for atenolol and placebo is similar, causal relationship to atenolol is uncertain.

Source: FDA prescribing information (DailyMed). Set ID: dfbd0160-f56a-41b9-a4ff-eb2df73b1e9b. SPL document ID: 5a096846-d052-28cd-e063-6294a90a1f46. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Atenolol/Chlorthalidone (FDA label)

Atenolol and chlorthalidone tablets are contraindicated in patients with: sinus bradycardia; heart block greater than first degree; cardiogenic shock; overt cardiac failure (see WARNINGS ); anuria; hypersensitivity to this product or to sulfonamide-derived drugs.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Atenolol/Chlorthalidone (FDA label)

Atenolol and chlorthalidone tablets may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone tablets plus a catecholamine depletor (e.g., reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone tablets (See WARNINGS .) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrine. Thiazides may increase the responsiveness to tubocurarine.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Start Your Risk-Free Trial